Public Comment and Testimony

Public Comment by The AIDS Institute to the Presidential Advisory Council on HIV/AIDS

September 29, 2011

We believe the new direction outlined by the CDC will better help decrease the overall number of new HIV infections in the US and achieve the goals of the National HIV/AIDS Strategy by applying federal funding to where it is most urgently needed.

Public Comment by The AIDS Institute before the Presidental Advisory Council on HIV/AIDS

August 2, 2011

Congratulations on your letter to the President and the Secretary which details your suggested next steps in implementing the National HIV/AIDS Strategy.

Public Comment by The AIDS Institute before the Presidential Advisory Council on HIV/AIDS

May 26, 2011

The AIDS Institute is asking you to support an increase of at least $106 million, which is the authorized level under the Ryan White HIV/AIDS Treatment Extension Act of 2009

The AIDS Institute's Testimony in Support of FY12 Domestic HIV/AIDS & Hepatitis Programs

May 20, 2011

The Subcommittee on Labor, Health and Human Services, Education, and Related Agencies
Senate Committee on Appropriations

Public Comments by TAI before CDC/HRSA Advisory Committee on HIV & STD Prevention and Treatment

May 11, 2011

We ask you to keep the ADAP crisis at the top of your agenda and to continue to urge the Obama Administration to address this situation.  Asking states to lower eligibility requirements, which HRSA is now doing, is not an answer.

The AIDS Institute's Written Testimony to the House Appropriations Labor HHS Subcommittee in Support of Funding Domestic HIV and Hepatitis Programs in FY12

April 15, 2011

Written Statement of Carl Schmid, Deputy Executive Director, The AIDS Institute to the Subcommittee on Labor, Health and Human Services, Education, and Related Agencies House Committee on Appropriations

Public Comment by The AIDS Institute before the Presidential Advisory Council on HIV/AIDS

PUBLIC COMMENT by CARL SCHMID, DEPUTY EXECUTIVE DIRECTOR, THE AIDS INSTITUTE
before the PRESIDENTIAL ADVISORY COUNCIL ON HIV/AIDS

January 27, 2011
Washington, DC

The AIDS Institute Statement on Programs to Support During the FY11 Appropriations Conference Process

The AIDS Institute would particularly like the Committees to focus on increased funding for the Ryan White AIDS Drug Assistance Program (ADAP) and HIV prevention funding at the Centers for Disease Control and Prevention (CDC).
November 4, 2010
Washington, DC

TAI Public Comments on FDA Approval Pathway for Biosimilar and Interchangeable Biological Products

Public Comment by James Sykes, Director of Global Policy, The AIDS Institute before the Food and Drug Administration
Approval Pathway for Biosimilar and Interchangeable Products
November 2, 2010
Washington, DC

Food and Drug Administration (FDA)
Syndicate content